

1 **Neurons expressing pathological Tau protein trigger dramatic changes** 2 **in microglial morphology and dynamics**

3
4 **Rahma Hassan-Abdi^{1,2}, Alexandre Brenet^{1,2}, Mohamed Bennis³, Constantin Yanicostas^{1,2} and**
5 **Nadia Soussi-Yanicostas^{1,2*}**

6 ¹INSERM, UMR1141, Hôpital Robert Debré, Paris, France

7 ²Université Paris Diderot, Sorbonne Paris Cité, Paris, France

8 ³Université Cadi Ayyad, Marrakesh, Morocco

9 10 *** Correspondence:**

11 Dr. Nadia Soussi-Yanicostas

12 nadia.soussi@inserm.fr

13 **Keywords: Microglia, Tauopathy, Tau protein, Zebrafish, *In vivo* imaging, Tau**
14 **hyperphosphorylation, Pro-inflammatory cytokines.**

15

16 **Abstract**

17 Microglial cells, the resident macrophages of the brain, are important players in the pathological
18 process of numerous neurodegenerative disorders, including tauopathies, a heterogeneous class of
19 diseases characterized by intraneuronal Tau aggregates. However, microglia response in Tau
20 pathologies remains poorly understood. Here we exploit a genetic zebrafish model of tauopathy,
21 combined with live microglia imaging, to investigate the behaviour of microglia *in vivo* in the disease
22 context. Results show that while microglia were almost immobile and displayed long and highly
23 dynamic branches in a wild-type context, in presence of diseased neurons cells became highly mobile
24 and displayed morphological changes, with highly mobile cell bodies together with fewer and shorter
25 processes. We also imaged, for the first time to our knowledge, the phagocytosis of apoptotic
26 tauopathic neurons by microglia *in vivo* and observed that microglia engulfed about as twice materials
27 as in controls. Finally, genetic ablation of microglia in zebrafish tauopathy model significantly
28 increased Tau hyperphosphorylation, suggesting that microglia provide neuroprotection to diseased
29 neurons. Our findings demonstrate for the first time the dynamics of microglia in contact with
30 tauopathic neurons *in vivo* and open perspectives for the real-time study of microglia in many neuronal
31 diseases.

32 1 Introduction

33 Microglia, the resident brain macrophages, are highly plastic and multifunctional cells that
34 continuously monitor the health of neuronal networks (Kierdorf and Prinz, 2017). In a physiological
35 context, microglia display long cytoplasmic processes that constantly extend and retract to contact
36 neighbour neurons and check their physiology (Nimmerjahn et al., 2005; Peri and Nüsslein-Volhard,
37 2008). Microglia also respond promptly to brain injury or infection, with both immuno-protective and
38 cytotoxic responses, including the secretion of a large set of cytokines (Butovsky and Weiner, 2018;
39 Hanisch, 2002; Hu et al., 2015; Wake et al., 2013) and increased phagocytic capacities to eliminate
40 pathogen debris and dead cells (Leong and Ling, 1992; Ling and Wong, 1993; Brockhaus et al., 1996;
41 Nakajima and Kohsaka, 2001; Hanisch and Kettenmann, 2007; Thameem Dheen et al., 2007).
42 However, in some disease contexts, such as tauopathies, microglia also appear to have harmful
43 activities (Bhaskar et al., 2010; Eyo and Dailey, 2013; Maphis et al., 2015; Laurent et al., 2018).

44 Tauopathies are a family of neurodegenerative disorders characterized by intra-neuronal fibrillary
45 aggregates containing abnormally hyperphosphorylated isoforms of the microtubule-associated protein
46 Tau (Alavi Naini and Soussi-Yanicostas, 2015; Spillantini and Goedert, 2013; Wang and Mandelkow,
47 2016). While the causal role of Tau in the disease is supported by several inherited tauopathies triggered
48 by dominant missense mutations in the protein, such as Tau^{P301L}, causing fronto-temporal dementia
49 with parkinsonism on chromosome 17 (FTDP-17) (Hutton et al., 1998), the aetiology of these disorders
50 and the contribution of microglia to their physiopathology remain poorly understood (Hansen et al.,
51 2018; Laurent et al., 2018; Perea et al., 2018).

52 Because of their plasticity and well-established neuroprotective activities, microglial cells are very
53 promising therapeutic targets for the treatment of neuron disorders, including neurodegenerative
54 diseases.

55 In an attempt to describe the behavior of microglial cells in a tauopathy disease context *in vivo*,
56 we used the transgenic zebrafish Tg(HuC-hTau^{P301L}:DsRed) tauopathy model (Paquet et al., 2009) and
57 live microglia imaging (Peri and Nüsslein-Volhard, 2008). We observed that in the presence of
58 hTau^{P301L}-expressing neurons, microglia display dramatic changes in morphology and dynamics, with
59 cells showing fewer and shorter branches and amoeboid-like cell bodies alongside a markedly
60 increased mobility and phagocytic activity. We also imaged the phagocytosis of dying neurons by
61 microglia and showed that these cells could phagocytose nearly twice as much as in homeostatic brains.
62 However, we also observed that these microglial cells failed to phagocytose all dead neurons,
63 highlighting the limits of their phagocytosing abilities.

64

65 2 Results

66 2.1 Microglia display dramatic changes in shape and dynamics in the presence of hTau^{P301L}- 67 expressing neurons

68 To investigate the behavior of microglial cells in a tauopathy disease context *in vivo*, we used the
69 transgenic Tg(HuC-hTau^{P301L}:DsRed) zebrafish model of Tau-induced neurodegeneration, combined
70 with the transgenic Tg(ApoE-eGFP) microglia marker line. As previously shown, in the optic tectum
71 of Tg(ApoE-eGFP) embryos, microglia displayed a ramified morphology, with a small cell body and
72 several elongated branches (Figures 1A,C). By contrast, in Tg(ApoE-eGFP; HuC-hTau^{P301L}:DsRed)
73 embryo microglia displayed a rounder morphology, with a larger cell body and fewer, shorter branches

74 (Figures 1B,B',D). Quantifications of morphological parameters confirmed these dramatic changes in
75 microglia morphology seen in the presence of diseased neurons, with a smaller surface area (Figure
76 1E) and volume (Figure 1F); and a greater sphericity (Figure 1G). However, alongside these rounded
77 microglia, a few branched cells were also observed in the disease context (Figures 1B, B').

78 Given that microglial cells are highly dynamic, we used *in vivo* real-time confocal imaging
79 combined with Imaris software (Bitplane Inc.) image analysis to determine whether the presence of
80 hTau^{P301L}-expressing neurons modified microglia dynamics. In Tg(ApoE-eGFP) embryos, microglia
81 displayed dynamic processes that were constantly extending and retracting, while their cell bodies
82 remained almost immobile (Figures 1H,J, Video 1, Supplementary figures 1A,C, Video 5). By contrast,
83 in Tg(ApoE-eGFP; HuC-hTau^{P301L}:DsRed) embryos, microglia were highly mobile with their cell
84 bodies traveling over longer distances (Figures 1I,K, Video 2, Supplementary figures 1B,D, Video 6).
85 Quantifications of microglia dynamics confirmed that in the presence of hTau^{P301L}-expressing neurons,
86 microglia displayed increased mean process speed (Figure 1L) and mean process track displacement
87 (Figure 1M), and a much larger displacement of the cell bodies over a similar time frame (Figure 1N).

88 To further characterize the phenotype of microglial cells exposed to hTau^{P301L}-expressing neurons,
89 we analysed the expression levels of the pro-inflammatory cytokines, IL-1 β , IL-8 and TNF- α in the
90 brain tissue of transgenic Tg(HuC-hTau^{P301L}:DsRed) and wild-type embryos. Unexpectedly, none of
91 these cytokines were overexpressed in the pathologic context, the two tested groups displaying no
92 significant differences in expression levels of IL-1 β , IL-8 (Figures 1O,P) and TNF- α (data not shown).

93

94 2.2 Genetic depletion of microglia worsens pathology in Tg(HuC-hTau^{P301L}:DsRed) embryos

95 As a first attempt to investigate the function of microglial cells in Tau pathology, we generated
96 Tg(HuC-hTau^{P301L}:DsRed) embryos completely devoid of microglia following injection of an
97 antisense morpholino oligonucleotide targeting pU.1 (MO-pU1) transcripts encoding a transcription
98 factor essential for proper differentiation of macrophage/microglia (Rhodes et al., 2005), and then
99 studied the consequences of such microglial cell ablation on Tau phosphorylation, neuron apoptosis
100 and expression of pro-inflammatory cytokines. Injection of the MO-pU1 (Figure 2A) leads to a
101 complete absence of microglial cells in the brain of the embryos as shown by either Neutral Red
102 staining (Figure 2B), or immunocytochemistry using L-plastin antibody (Figure 2C).

103 Using 5 dpf wild-type and transgenic Tg(HuC-hTau^{P301L}:DsRed) embryos and microglia ablation
104 following MO-pU1 injection, we first studied the consequences of the absence of microglia on the
105 expression of pro-inflammatory cytokines IL-1 β and IL-8. Results showed that while expression of
106 Tau^{P301L} did not stimulate overexpression of IL-1 β (Figure 2D) and IL-8 (Figure 2E) in embryos with
107 microglia embryos, microglia depletion in Tg(HuC-hTau^{P301L}:DsRed) embryos provoked a markedly
108 increased expression of both these pro-inflammatory cytokines.

109 As a first attempt to determine the effect of the absence of microglia on Tau hyperphosphorylation
110 *in vivo*, we quantified and compared hTau phosphorylation levels at Ser396 site in Tg(HuC-
111 hTau^{P301L}:DsRed) embryos with and without microglia (Figure 2F). Interestingly, in Tg(HuC-
112 hTau^{P301L}:DsRed) embryos without microglia, we observed an increased accumulation of
113 hyperphosphorylated Tau when compared to that seen in their siblings with microglia (Figure 2F).

114 Quantification of phospho-Tau to total Tau accumulation ratio (pTau/Tau) confirmed that hTau
115 hyperphosphorylation levels were significantly increased in microglia-depleted Tg(HuC-
116 hTau^{P301L}:DsRed) embryos (Figure 2G). To further investigate the consequences of the absence of
117 microglia on Tau hyperphosphorylation, Tg(HuC-hTau^{P301L}:DsRed) mutant embryos, which are fully
118 devoid of microglia as the result of homozygous *nrc3-like*^{st73} mutation (Shiau et al., 2013), and
119 analyzed hTau^{P301L} hyperphosphorylation using the antibody PHF1, targeting pathological
120 phosphorylation sites Ser396 and Ser404 of the hTau protein (Figures 2H,I). In good agreement with
121 Western blot analysis, a significant increase in PHF1 labelling intensity was observed in the
122 telencephalon of 6 dpf Tg(HuC-hTau^{P301L}:DsRed; *nrc3-like*^{st73/73}) mutant embryos (Figure 2I) when
123 compared to that observed in the brain of their Tg(HuC-hTau^{P301L}:DsRed; *nrc3-like*^{st73/+}) siblings with
124 microglia (Figure 2H). Quantification of the signal ratio of hyperphosphorylated hTau protein on brain
125 sections from Tg(HuC-hTau^{P301L}:DsRed; *nrc3-like*^{st73/73}) embryos confirmed the significant increase
126 of this ratio displayed in protein extracts from Tg(HuC-hTau^{P301L}:DsRed) embryos microglia-depleted
127 with morpholino (Figure 2J).

128

129 2.3 Microglia phagocytic activity is enhanced in the presence of hTau^{P301L}-expressing neurons

130 As phagocytosis is a main feature of microglial cells, we first monitored the phagocytic activity of
131 microglia in Tg(ApoE-eGFP; HuC-hTau^{P301L}:DsRed) embryos. We observed the phagocytosis of
132 hTau^{P301L}-expressing neurons by microglia, using confocal real-time imaging (Figure 3B, Video 3). A
133 microglial cell in the optic tectum (Figures 3B,C,0 min) sends one of its processes to the pathological
134 neuron (Figures 3B,C,5 min) to draw it towards its cell body (Figures 3B,C,9 min) and execute the
135 digestion of the neuron and its debris until completion of the process (Figures 3B,C,18 min). We also
136 observed the detail of a microglial cell engulfing three neurons simultaneously (Supplementary figure
137 2, Video 7). We next assessed the phagocytic activity of microglia by quantifying the total engulfed
138 volume, which was significantly increased in Tg(ApoE-eGFP; HuC-hTau^{P301L}:DsRed) embryos
139 (Figure 3D). Given the critical role of microglia in removing apoptotic cells and other noxious
140 elements, we next visualized neuronal death in Tg(ApoE-eGFP; HuC-hTau^{P301L}:DsRed) embryos using
141 the apoptotic marker Acridine Orange. Data showed that microglia specifically engulfed apoptotic
142 neurons (Figures 3E-F, Video 4) but not non-apoptotic hTau^{P301L}-expressing cells, supporting the
143 notion that microglia specifically responds to signals sent by degenerating neurons that are already
144 apoptotic but not hTau^{P301L}-expressing neurons *per se*. However, quantification of the number of non-
145 engulfed apoptotic neurons in Tg(ApoE-eGFP; HuC-hTau^{P301L}:DsRed) and control Tg(ApoE-eGFP;
146 HuC-RFP) embryos showed that microglia failed to phagocyte all apoptotic hTau^{P301L}-expressing
147 neurons (Figure 3K).

148

149 3 Discussion

150 To date, few studies have been conducted in *in vivo* conditions in healthy mice brains to show
151 detailed morphological characterization of microglia (Cătălin et al., 2017; Sun et al., 2019). However,
152 all studies aimed at investigating the physiology of microglia or their interactions with neurons in

153 rodent models of neuronal diseases have relied widely on *ex vivo* and *in vitro* approaches, which cannot
154 accurately reproduce the complexity of the physiological conditions observed in living brains (Bemiller
155 et al., 2017; Hickman et al., 2013; Maphis et al., 2015; Rustenhoven et al., 2018).

156 While these marker-based approaches remain useful to gather prerequisite knowledge on immune
157 cells, it is nonetheless crucial to preserve the morphology and dynamics of these highly plastic cells,
158 which respond to very small changes in the CNS, and so to study them in a living brain (He et al.,
159 2018). Recent studies show that time spent by microglia *ex vivo* is associated with a different evolution
160 of gene expression until their expression levels become the reverse of the initial measures (Gosselin et
161 al., 2017).

162 The present work is, to our knowledge, the first aimed at characterizing the dynamic behavior of
163 microglial cells in the presence of pathological neurons expressing a human mutant Tau protein,
164 hTau^{P301L}, causing tauopathy.

165 Our results show that the presence of these hTau^{P301L}-expressing neurons caused dramatic changes
166 to microglia, with the cells displaying an amoeboid-like shape and higher mobility. Although these
167 morphological and dynamic changes are reminiscent of the classical microglial activation profile seen
168 in response to injury or disease (Nakajima and Kohsaka, 2001), these rounded microglial cells did not
169 overexpress known pro-inflammatory cytokines, IL-1 β and IL-8 showing that the observed changes
170 were noninflammatory (Zhao et al., 2018). However, genetic depletion of microglia in brains
171 containing hTau^{P301L}-expressing neurons induced a markedly increased expression of both pro-
172 inflammatory cytokines. This increased cytokine expression is reminiscent to that observed in a model
173 of prion-induced neurodegeneration in mice (Zhu et al., 2016). One possible hypothesis is that
174 astrocytes, the largest glial group, can also produce pro-inflammatory factors and exhibit a reactive
175 state as it has been reported in tauopathy mice models (Sidoryk-Wegrzynowicz et al., 2017). This
176 neuroinflammation could be exacerbated by the higher levels of pathological hyperphosphorylated Tau
177 protein (Martini-Stoica et al., 2018; Perea et al., 2019).

178 In Tg(HuC-hTau^{P301L}:DsRed) embryos, highly dynamic microglial cells displayed an intense
179 phagocytic activity, specifically eliminating nearly twice as many apoptotic neurons as microglial cells
180 in healthy brains. However, the significantly higher number of non-engulfed apoptotic neurons in
181 tauopathic brains suggests that these microglial cells are overwhelmed by the excessive neuron death
182 rate generated in this transgenic model. One therapeutic approach might thus be to enhance the
183 phagocytic activity of microglia to slow the spread of the disease.

184 This study using intact zebrafish brain visualizes interactions between microglia and hTau^{P301L}-
185 expressing neurons in real time and sheds light on microglia activities exerting a protective role mainly
186 through specific phagocytosis of apoptotic hTau^{P301L}-expressing neurons, thereby limiting the spread
187 of noxious cell bodies or pathologic hyperphosphorylated Tau. However, while displaying enhanced
188 phagocytic activity towards hTau^{P301L}-expressing neurons and efficiently eliminating dead neurons,
189 microglial cells appeared overwhelmed, as evidenced by the higher number of dead, albeit non-
190 engulfed dead neurons in transgenic embryo brains. These findings support therapeutic approaches
191 based on the modulation of microglial phagocytic activity in a specific neurodegenerative context.

192

193

194

195 4 Materials and methods

196 4.1 Ethics statement

197 All the animal experiments described in the present study were conducted at the French National
198 Institute of Health and Medical Research (INSERM) UMR 1141 in Paris in accordance with European
199 Union guidelines for the handling of laboratory animals
200 (http://ec.europa.eu/environment/chemicals/lab_animals/home_en.htm) and were approved by the
201 Direction Départementale de la Protection des Populations de Paris and the French Animal Ethics
202 Committee under reference No. 2012-15/676-0069.

203 4.2 Zebrafish lines and maintenance

204 Zebrafish were maintained at 26.5 °C in 14 h light and 10 h dark cycles. Embryos were collected by
205 natural spawning and to avoid pigmentation, 0.003% 1-phenyl-2-thiourea (PTU) was added at 1 dpf
206 (day post-fertilization). Transgenic Tg(HuC-hTau^{P301L}:DsRed) embryos (Paquet et al., 2009), showing
207 mosaic neuronal expression of hTau^{P301L} mutant protein, linked to FTDP-17, was used to reproduce key
208 pathological features of tauopathy. In order to simultaneously observe microglia, we used the
209 Tg(ApoE-eGFP) transgenic line (Peri and Nüsslein-Volhard, 2008) that allows live imaging of
210 microglial cells with GFP. To investigate the consequences of the absence of microglia, we used the
211 *nlr3-like*^{st73/st73} mutants (Shiau et al., 2013), in which the st73 recessive loss of function mutation in
212 the noncanonical NOD-like receptor (NLR) gene is responsible for the absence of microglia in the
213 brain.

214 4.3 Confocal imaging

215 For *in vivo* imaging, 7 dpf larvae were anaesthetized with 112 µg/ml 3-aminobenzoic acid ethyl ester
216 (tricaine, Sigma), immobilized in 1.2% low melting-point agarose in the centre of a 35 mm glass-
217 bottomed dish (Corning®), and covered with E3 medium containing 112 µg/ml tricaine. Images were
218 acquired using a Leica SP8 confocal scanning laser microscope equipped with a Leica 20x/0.75 multi-
219 immersion objective equipped with an Olympus 40x/1.1 water objective; or a Leica DM6000FS
220 Spinning disk L2 microscope equipped with a Leica 25x/0.95 water immersion objective. All the
221 images were then processed using LAS-X (Leica), MetaMorph 7.8.9 (Molecular Devices), AutoQuant
222 X3.1.1 (Media Cybernetics), Fiji (Version 2.0.0-rc-65/1.52b) and Adobe Photoshop 7.0 (Adobe
223 System).

224 4.4 Image analysis

225 The surface area, volume and sphericity ($\Psi = \frac{1}{\pi^{\frac{1}{3}}(6V_p)^{\frac{2}{3}}}$) of microglial cells were quantified using Imaris
226 MeasurementPro (Bitplane Inc.). The speed (distance travelled per unit time) and displacement
227 (distance between first and last positions) of microglial processes were analysed using Imaris Filament
228 tracer (Bitplane Inc.) on 15 minute long time-lapses. Microglial cell body displacements (distance
229 between first and last positions) were tracked with Imaris MeasurementPro on 30 minute long time-
230 lapses. Three-dimensional cell reconstructions were created using Imaris MeasurementPro.

231 4.5 Ablation of microglia

232 Morpholino pU.1 (MO-pU1): 5'-GATATACTGATACTCCATTGGTGGT-3' designed to inhibit *pU1*
233 mRNA translation, was obtained from Gene Tools. 2 nl of a 0.5 mM solution, corresponding to 1 pmol
234 of pU.1 morpholino was injected into 1 to 2 cells stage embryos using standard protocols. After
235 injection, the embryos were incubated in E3 medium at 28.5 °C until analysis at the desired stage. To

236 select embryos in which microglia differentiation was fully blocked, Neutral Red staining was used to
237 label microglia. Embryos were incubated in Neutral Red diluted in E3 medium for 5-8 hours at 28.5 °C,
238 and rinsed 10 min before examination using a stereomicroscope (Zeiss).

239 **4.6 Apoptosis labelling**

240 To visualize apoptotic neurons, embryos were incubated in an Acridine Orange solution (1:500,
241 VectaCell) for 20 min at 28.5 °C in the dark, and rinsed twice for 10 min in E3 medium. Although both
242 GFP and acridine orange have very close excitation and emission spectra, their signals are easily
243 distinguishable, with acridine orange emitting a much more intense fluorescence. Therefore, GFP
244 channel (green) also shows Acridine Orange staining (blue) (Figure 3F).

245 **4.7 Immunocytochemistry**

246 6 dpf Tg(HuC-hTau^{P301L}:DsRed; *nlr3-like*^{st73/+}) and Tg(HuC-hTau^{P301L}:DsRed; *nlr3-like*^{st73/73})
247 embryos were anaesthetized in 0.2% tricaine, fixed with 4% paraformaldehyde, cryoprotected in 10%
248 sucrose solution prior to flash freezing in isopentane. Samples were stored at -80°C until use. Embryos
249 were cut into 20-µm-thick sections on cryostat, mounted on superfrost slides, and stored at -80°C.
250 Cryosections (20 µm) were fixed in 4% paraformaldehyde at room temperature for 10 min. After
251 washing thrice with PBS, sections were treated with 0.25% trypsin in 1X PBS for 2 min at 25°C.
252 Immunohistochemistry was performed as previously described (Puverel et al., 2009). Briefly, sections
253 were blocked and permeabilized with 0.2% gelatin, 0.25% Triton X-100 diluted in 1X PBS for 1 hr at
254 room temperature and then incubated overnight at room temperature with anti-PHF1 (1:100, mouse
255 monoclonal, gift of Dr. Peter Davies, Albert Einstein College of Medicine, New York, USA) After
256 several washes, sections were incubated for 1 hr with the donkey anti-mouse coupled to Alexa Fluor
257 488 (1:500, Jackson Laboratories, West Grove, PA). Sections were counterstained for 10 min with
258 0.1% DAPI (Sigma-Aldrich) before being mounted with Vectashield Mounting Medium (Vector).
259 Sections were analyzed using a Leica TCS SP8 confocal scanning system (Leica Microsystems).
260 Images were acquired using a Leica SP8 confocal scanning laser microscope equipped with a Leica
261 20x/0.75 multi-immersion objective. Images were processed with LAS-X (Leica), Fiji (Version 2.0.0-
262 rc-65/1.52b) and Adobe Photoshop 7.0 (Adobe System).

263 For whole mount immunostaining, 5 dpf wild-type embryos with or without microglia, were fixed in
264 4% formaldehyde in PBS for 1 hour 30 minutes at room temperature, washed three times in PBS (10
265 minutes each) and permeabilized in cold acetone (-20°C) for 20 minutes. After several washes, embryos
266 were incubated in collagenase solution for 1 hour. Immunocytochemistry was performed as described
267 previously (Naini et al., 2018) using rabbit anti-zebrafish L-plastin polyclonal antibody (gift of Dr.
268 Michael Redd, University College London, United Kingdom), followed by Alexa-coupled secondary
269 anti-rabbit antibody (Molecular Probes) at 1:500 dilution. After washing, the fluorescence was
270 analyzed using a Leica TCS SP8 confocal scanning system (Leica Microsystems). Images were
271 collected using a Leica 20x/0.75 multi-immersion objective. Images were processed with LAS-X
272 (Leica), Fiji (Version 2.0.0-rc-65/1.52b) and Adobe Photoshop 7.0 (Adobe System).

273

274 **4.8 RT-qPCR**

275 Total RNAs were extracted from independent batches of 15 embryos each, using the NucleoSpin RNA
276 kit (Macherey Nagel, Germany). Concentration of RNAs were assessed by spectrophotometry using a
277 Nanodrop™ device (Thermoscientific, USA). Total RNA (1µg) samples were reverse transcribed
278 using the iScript™ cDNA synthesis kit (Bio-Rad, USA). RT-qPCR experiments were performed in

279 triplicate using SYBR Green Super-mix (Bio-Rad, USA) according to a program of 40 cycles in 3 steps
280 (denaturation of 5 seconds at 96 ° C, hybridization of 10 seconds at 60 ° C and extension of 10 seconds
281 at 72 ° C). Primers were designed manually following visual inspection of gene sequences. Gene
282 sequences and NCBI references are given in **Supplementary table 1**. Specific mRNA levels were
283 evaluated after normalization of the results with tubulin- α (*tuba1*) mRNA as reference, and the results
284 were indicated in arbitrary units determined respectively to the levels of RNA determined in wild-type
285 embryos and assessed using a Welch two-sample t-test or an ANOVA followed by a Tukey post-test.

286 **4.9 Western blot**

287 5 dpf embryos were collected, anaesthetized and lysed on ice with lysis buffer (50 mM Tris-HCl,
288 320mM Sucrose, pH 7.4) supplemented with protease and phosphatase inhibitors (Roche). Lysates
289 were homogenized by sonication (thrice 10 seconds) and centrifuged at 600 g for 10 min. Samples
290 containing 10 μ g proteins were subjected to SDS-PAGE in 4-20% gradient acrylamide gel. Primary
291 antibody against phosphorylated tau, Ser396 (1:1000, mouse monoclonal, Ozyme); and anti-human
292 total tau antibody (1:1000, rabbit polyclonal, Dako Cytomation) were used. Subsequently, the blots
293 were incubated for 1 hour at room temperature with the corresponding secondary antibodies (anti-
294 mouse or anti-rabbit, 1:5000, Cell Signalling Technology) diluted in bovine serum albumin solution
295 and developed with ECL RevelBIOt[®] Plus (Ozyme) following manufacturer's instructions. All
296 statistics were assessed using a Welch two-sample t-test and all data are indicated as means \pm SEM.

297 **4.10 Statistics**

298 All statistics were assessed using a Welch two-sample *t*-test or an ANOVA followed by a Tukey post-
299 test. All data are represented as means \pm SEM.

300 **5 Conflict of Interest**

301 The authors declare that the research was conducted in the absence of any commercial or financial
302 relationships that could be construed as a potential conflict of interest.

303 **6 Funding**

304 This work was supported by Institut National de la Santé et la Recherche Médicale (INSERM), the
305 National Center for Scientific Research (CNRS), the French National Research Agency (ANR-16-
306 CE18-0010), and Fondation NRJ (Institut de France) to NSY. Funding sources had no involvement in
307 study design, collection, analysis or interpretation of data, or decision to publish.

308 **7 Acknowledgments**

309 We thank Bettina Schmid (DZNE, Munich, Germany) for providing us with the Tg(HuC-
310 hTau^{P301L}:DsRed) transgenic line, Francesca Peri (University of Zurich, Zurich, Switzerland) for
311 providing us with the Tg(ApoE-eGFP) and Michael Redd (University College London, London, United
312 Kingdom) for providing us with the rabbit anti-zebrafish L-plastin polyclonal antibody. We also thank
313 the imaging facility IMAG'IC (Cochin Institute, Paris). We also thank Christiane Romain and Olivier
314 Bar (INSERM UMR 1141) for their technical assistance.

315

316


317 **Bibliography**

- 318 A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation
319 (2009). *J. Clin. Invest.* 119, 1382–1395. doi:10.1172/JCI37537.
- 320 Alavi Naini, S. M., and Soussi-Yanicostas, N. (2015). Tau Hyperphosphorylation and Oxidative
321 Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies? *Oxid. Med. Cell. Longev.*
322 2015. doi:10.1155/2015/151979.
- 323 Bemiller, S. M., McCray, T. J., Allan, K., Formica, S. V., Xu, G., Wilson, G., et al. (2017). TREM2
324 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of
325 tauopathy. *Mol. Neurodegener.* 12. doi:10.1186/s13024-017-0216-6.
- 326 Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M., and Lamb, B. T.
327 (2010). Regulation of Tau Pathology by the Microglial Fractalkine Receptor. *Neuron* 68, 19.
328 doi:10.1016/j.neuron.2010.08.023.
- 329 Brockhaus, J., Möller, T., and Kettenmann, H. (1996). Phagocytosing ameboid microglial cells
330 studied in a mouse corpus callosum slice preparation. *Glia* 16, 81–90. doi:10.1002/(SICI)1098-
331 1136(199601)16:1<81::AID-GLIA9>3.0.CO;2-E.
- 332 Butovsky, O., and Weiner, H. L. (2018). Microglial signatures and their role in health and disease.
333 *Nat. Rev. Neurosci.* doi:10.1038/s41583-018-0057-5.
- 334 Cătălin, B., Stopper, L., Bălșeanu, T.-A., and Scheller, A. (2017). The in situ morphology of
335 microglia is highly sensitive to the mode of tissue fixation. *J. Chem. Neuroanat.* 86, 59–66.
336 doi:10.1016/j.jchemneu.2017.08.007.
- 337 Eyo, U. B., and Dailey, M. E. (2013). Microglia: Key elements in neural development, plasticity, and
338 pathology. *J. Neuroimmune Pharmacol.* 8, 494–509. doi:10.1007/s11481-013-9434-z.
- 339 Gosselin, D., Gosselin, D., Skola, D., Coufal, N. G., Holtman, I. R., Johannes, C. M., et al. (2017).
340 An environment-dependent transcriptional network specifies human microglia identity. 3222,
341 33–35.
- 342 Hanisch, U. K. (2002). Microglia as a source and target of cytokines. *Glia* 40, 140–155.
343 doi:10.1002/glia.10161.
- 344 Hanisch, U. K., and Kettenmann, H. (2007). Microglia: Active sensor and versatile effector cells in
345 the normal and pathologic brain. *Nat. Neurosci.* 10, 1387–1394. doi:10.1038/nn1997.
- 346 Hansen, D. V., Hanson, J. E., and Sheng, M. (2018). Microglia in Alzheimer’s disease. *J. Cell Biol.*
347 217, 459–472. doi:10.1083/jcb.201709069.
- 348 He, Y., Yao, X., Taylor, N., Bai, Y., Lovenberg, T., and Bhattacharya, A. (2018). RNA sequencing
349 analysis reveals quiescent microglia isolation methods from postnatal mouse brains and
350 limitations of BV2 cells. *J. Neuroinflammation* 15. doi:10.1186/s12974-018-1195-4.
- 351 Hickman, S. E., Kingery, N. D., Ohsumi, T. K., Borowsky, M. L., Wang, L., Means, T. K., et al.
352 (2013). The microglial sensome revealed by direct RNA sequencing. *Nat. Neurosci.* 16, 1896–


- 353 1905. doi:10.1038/nn.3554.
- 354 Hu, X., Leak, R. K., Shi, Y., Suenaga, J., Gao, Y., Zheng, P., et al. (2015). Microglial and
355 macrophage polarization - New prospects for brain repair. *Nat. Rev. Neurol.* 11, 56–64.
356 doi:10.1038/nrneuro.2014.207.
- 357 Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H. H., et al. (1998).
358 Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-
359 17. *Nature* 393, 702–704. doi:10.1038/31508.
- 360 Kierdorf, K., and Prinz, M. (2017). Microglia in steady state. *J. Clin. Invest.* 127, 3201–3209.
361 doi:10.1172/JCI90602.
- 362 Laurent, C., Buée, L., and Blum, D. (2018). Tau and neuroinflammation: What impact for
363 Alzheimer's Disease and Tauopathies? *Biomed. J.* 41, 21–33. doi:10.1016/j.bj.2018.01.003.
- 364 Leong, S. -K, and Ling, E. -A (1992). Amoeboid and ramified microglia: Their interrelationship and
365 response to brain injury. *Glia* 6, 39–47. doi:10.1002/glia.440060106.
- 366 Ling, E. -A, and Wong, W. -C (1993). The origin and nature of ramified and amoeboid microglia: A
367 historical review and current concepts. *Glia* 7, 9–18. doi:10.1002/glia.440070105.
- 368 Maphis, N., Xu, G., Kokiko-cochran, O. N., Cardona, A., Ransohoff, R. M., Lamb, B. T., et al.
369 (2015a). Loss of tau rescues inflammation-mediated neurodegeneration. *Front. Neurosci.* 9, 1–
370 12. doi:10.3389/fnins.2015.00196.
- 371 Maphis, N., Xu, G., Kokiko-Cochran, O. N., Jiang, S., Cardona, A., Ransohoff, R. M., et al. (2015b).
372 Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the
373 brain. *Brain* 138, 1738–1755. doi:10.1093/brain/awv081.
- 374 Martini-Stoica, H., Cole, A. L., Swartzlander, D. B., Chen, F., Wan, Y.-W., Bajaj, L., et al. (2018).
375 TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. *J. Exp.*
376 *Med.* 215, 2355–2377. doi:10.1084/JEM.20172158.
- 377 Naini, S. M. A., Yanicostas, C., Hassan-Abdi, R., Blondeel, S., Bennis, M., Weiss, R. J., et al.
378 (2018). Surfen and oxalyl surfen decrease tau hyperphosphorylation and mitigate neuron deficits
379 in vivo in a zebrafish model of tauopathy. *Transl. Neurodegener.* 7, 6. doi:10.1186/s40035-018-
380 0111-2.
- 381 Nakajima, K., and Kohsaka, S. (2001a). Microglia: Activation and their significance in the central
382 nervous system. *J. Biochem.* doi:10.1093/oxfordjournals.jbchem.a002969.
- 383 Nakajima, K., and Kohsaka, S. (2001b). Microglia: Activation and their significance in the central
384 nervous system. Oxford University Press doi:10.1093/oxfordjournals.jbchem.a002969.
- 385 Nimmerjahn, A., Kirchhoff, F., and Helmchen, F. (2005). Resting microglial cells are highly
386 dynamic surveillants of brain parenchyma in vivo. *Science (80-.)*. 308, 1314–1318.
387 doi:10.1126/science.1110647.
- 388 Paquet, D., Bhat, R., Sydow, A., Mandelkow, E. M., Berg, S., Hellberg, S., et al. (2009). A zebrafish

- 389 model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. *J. Clin.*
390 *Invest.* 119, 1382–1395. doi:10.1172/JCI37537.
- 391 Perea, J. R., Llorens-Martín, M., Ávila, J., and Bolós, M. (2018). The Role of Microglia in the Spread
392 of Tau: Relevance for Tauopathies. *Front. Cell. Neurosci.* 12. doi:10.3389/fncel.2018.00172.
- 393 Perea, J. R., López, E., Díez-Ballesteros, J. C., Ávila, J., Hernández, F., and Bolós, M. Extracellular
394 Monomeric Tau Is Internalized by Astrocytes. *Front. Neurosci.* doi:10.3389/fnins.2019.00442.
- 395 Peri, F., and Nüsslein-Volhard, C. (2008). Live Imaging of Neuronal Degradation by Microglia
396 Reveals a Role for v0-ATPase a1 in Phagosomal Fusion In Vivo. *Cell* 133, 916–927.
397 doi:10.1016/j.cell.2008.04.037.
- 398 Puverel, S., Nakatani, H., Parras, C., and Soussi-Yanicostas, N. (2009). Prokineticin receptor 2
399 expression identifies migrating neuroblasts and their subventricular zone transient-amplifying
400 progenitors in adult mice. *J. Comp. Neurol.* 512, 232–242. doi:10.1002/cne.21888.
- 401 Rhodes, J., Hagen, A., Hsu, K., Deng, M., Liu, T. X., Look, A. T., et al. (2005). Interplay of pu.1 and
402 Gata1 determines myelo-erythroid progenitor cell fate in zebrafish. *Dev. Cell* 8, 97–108.
403 doi:10.1016/j.devcel.2004.11.014.
- 404 Rustenhoven, J., Smith, A. M., Smyth, L. C., Jansson, D., Scotter, E. L., Swanson, M. E. V., et al.
405 (2018). PU.1 regulates Alzheimer’s disease-associated genes in primary human microglia. *Mol.*
406 *Neurodegener.* 13. doi:10.1186/s13024-018-0277-1.
- 407 Shiau, C. E., Monk, K. R., Joo, W., and Talbot, W. S. (2013). An Anti-inflammatory NOD-like
408 Receptor Is Required for Microglia Development. *Cell Rep.* 5, 1342–1352.
409 doi:10.1016/j.celrep.2013.11.004.
- 410 Sidoryk-Wegrzynowicz, M., Gerber, Y. N., Ries, M., Sastre, M., Tolkovsky, A. M., and Spillantini,
411 M. G. (2017). Astrocytes in mouse models of tauopathies acquire early deficits and lose
412 neurosupportive functions. *Acta Neuropathol. Commun.* 5, 89. doi:10.1186/s40478-017-0478-9.
- 413 Sousa, C., Golebiewska, A., Poovathingal, S. K., Kaoma, T., Pires-Afonso, Y., Martina, S., et al.
414 (2018). Single-cell transcriptomics reveals distinct inflammation-induced microglia signatures.
415 *EMBO Rep.* doi:10.15252/embr.201846171.
- 416 Spillantini, M. G., and Goedert, M. (2013). Tau pathology and neurodegeneration. *Lancet Neurol.* 12,
417 609–622. doi:10.1016/S1474-4422(13)70090-5.
- 418 Sun, W., Suzuki, K., Toptunov, D., Stoyanov, S., Yuzaki, M., Khiroug, L., et al. (2019). In vivo
419 Two-Photon Imaging of Anesthesia-Specific Alterations in Microglial Surveillance and
420 Photodamage-Directed Motility in Mouse Cortex. *Front. Neurosci.* 13, 421.
421 doi:10.3389/fnins.2019.00421.
- 422 Thameem Dheen, S., Kaur, C., and Ling, E.-A. (2007). Microglial Activation and its Implications in
423 the Brain Diseases. *Curr. Med. Chem.* 14, 1189–1197.
424 doi:http://dx.doi.org/10.2174/092986707780597961.
- 425 Wake, H., Moorhouse, A. J., Miyamoto, A., and Nabekura, J. (2013). Microglia: Actively surveying

- 426 and shaping neuronal circuit structure and function. *Trends Neurosci.* 36, 209–217.
427 doi:10.1016/j.tins.2012.11.007.
- 428 Wang, Y., and Mandelkow, E. (2016). Tau in physiology and pathology. *Nat. Rev. Neurosci.* 17, 5–
429 21. doi:10.1038/nrn.2015.1.
- 430 Zhao, X., Liao, Y., Morgan, S., Mathur, R., Feustel, P., Mazurkiewicz, J., et al. (2018).
431 Noninflammatory Changes of Microglia Are Sufficient to Cause Epilepsy. *Cell Rep.* 22, 2080–
432 2093. doi:10.1016/j.celrep.2018.02.004.
- 433 Zhu, C., Herrmann, U. S., Falsig, J., Abakumova, I., Nuvolone, M., Schwarz, P., et al. (2016). A
434 neuroprotective role for microglia in prion diseases. *J. Exp. Med.* 213, 1047–59.
435 doi:10.1084/jem.20151000.
- 436



438 **Figure 1. Microglia displays dramatic changes in morphology and dynamics in the presence of**
439 **hTau^{P301L}-expressing neurons.** (A, B, B') Dorsal views of the optic tectum of 7 dpf Tg(ApoE-eGFP)
440 (A) and Tg(ApoE-eGFP; HuC-hTau^{P301L}:DsRed) transgenic embryos (B, B'), showed the
441 characteristic ramified morphology of microglia in wild-type (A), while in the presence of hTau^{P301L}-
442 expressing neurons, microglial cells displayed shorter processes and larger cell bodies. (C, D) Detailed
443 morphology of microglial cells in Tg(ApoE-eGFP) (C) and Tg(ApoE-eGFP; HuC-hTau^{P301L}:DsRed)
444 embryos (D). (E-G) Measurements of microglia morphological parameters; surface area (E, $p <$
445 0.0001), volume (F, $p <$ 0.0001) and sphericity (G, $p <$ 0.0001), in Tg(ApoE-eGFP) (n=10) and
446 Tg(ApoE-eGFP; HuC-hTau^{P301L}:DsRed) (n=24) embryos, confirmed the cell shape changes observed
447 in the presence of hTau^{P301L}-expressing neurons. (H, I) Time-lapse sequences of microglia dynamics
448 in Tg(ApoE-eGFP) (H, Video 1) and Tg(ApoE-eGFP; HuC-hTau^{P301L}:DsRed) embryos (I, Video 2).
449 (J, K) Merged images of two time points separated by 15 minutes from video 1 (J) and video 2 (K).
450 The merged images at t=0 minutes (cyan) and t=15 minutes (red) highlighted the dramatic increased
451 mobility of microglial cell bodies in the presence of hTau^{P301L}-expressing neurons. (L-N)
452 Measurements of microglia dynamics; process speed (L, $p = 0.0004$), process track displacement (M,
453 $p = 0.0002$) and cell body displacement (N, $p = 0.0054$), in Tg(ApoE-eGFP) (n=3) and Tg(ApoE-
454 eGFP; HuC-hTau^{P301L}:DsRed) (n=4) embryos, confirmed the increased mobility of both microglia
455 processes and cell bodies observed in the presence of hTau^{P301L}-expressing neurons. (O, P)
456 Measurements of pro-inflammatory cytokine expression in the brain of 5 dpf Tg(ApoE-eGFP) (n=6)
457 and Tg(ApoE-eGFP; HuC-hTau^{P301L}:DsRed) (n=11) embryos. Comparison of the relative expression
458 of IL-1 β (O, $p = 0.80$) and IL-8 (P, $p = 0.89$) in both groups shows no significant differences. (Q)
459 Schematic dorsal view of a 7 dpf zebrafish embryo. The red square shows the region of interest that
460 comprises the optic tectum. ***: $p <$ 0.001; **: $p <$ 0.01; *: $p <$ 0.05. Scale bar (A, B, B', H, I, J, K)
461 = 50 μ m, (C, D) = 10 μ m. A.U.: arbitrary units.




462

463 **Figure 2. Genetic depletion of microglia worsens the pathology in Tg(HuC-hTau^{P301L}:DsRed)**
 464 **embryos.** (A) Outline of microglia depletion experiments. Embryos were injected at the single cell
 465 stage with a solution of antisense morpholino oligonucleotide targeting pU.1 transcripts. At 5 dpf,
 466 injected embryos were incubated in Neutral Red solution to sort microglia-depleted embryos. (B)
 467 Dorsal views of the optic tectum of 5 dpf wild-type microglia-depleted (B2) and untreated live embryos
 468 (B1), following incubation in Neutral Red solution. (C) Dorsal views of the optic tectum of 5 dpf wild-
 469 type microglia-depleted (C2) and untreated fixed embryos (C1), labelled with L-plastin antibody. (D,
 470 E) Measurements of pro-inflammatory cytokines in the brain of 5 dpf wild-type embryos with (n=6),
 471 or without (n=3) microglia; and Tg(HuC-hTau^{P301L}:DsRed) embryos with (n=11), or without microglia
 472 (n=7). Both relative expressions of IL-1β (D, *p* = 0.035) and IL-8 (E, *p* < 0.0001) display a significant
 473 increase in the brains of Tg(HuC-hTau^{P301L}:DsRed) embryos without microglia cells, compared to their
 474 siblings with microglial cells. (F, G) Representative Western blots membranes of total protein extracts
 475 from 6 dpf Tg(HuC-hTau^{P301L}:DsRed) embryos with (left) or without (right) microglia, hybridized with
 476 antibodies against human total Tau (total Tau) or human phosphorylated Tau at Ser396 residue (pTau)

477 (F); and quantification of corresponding pTau/total Tau ratio (respectively, n=4 and n=4) (G, $p = 0.01$).
 478 The ratio of hyperphosphorylated hTau to total Tau protein is significantly increased in microglia-
 479 depleted Tg(HuC-hTau^{P301L}:DsRed) embryos. (H-J) Dorsal views of the telencephalon of 6 dpf
 480 Tg(HuC-hTau^{P301L}:DsRed; *nlrc3-like*^{st73/+}) embryos (H) and Tg(HuC-hTau^{P301L}:DsRed; *nlrc3-*
 481 *like*^{st73/73}) embryos (I), labelled with an antibody directed against human phosphorylated Tau at Ser396
 482 and Ser404 residues (PHF1); and quantification of corresponding PHF1/hTau^{P301L}-DsRed signal ratio
 483 (respectively, n=4 and n=6) (J, $p = 0.0485$). The quantification of the signal ratio of
 484 hyperphosphorylated hTau protein on brain sections from Tg(HuC-hTau^{P301L}:DsRed; *nlrc3-like*^{st73/73})
 485 mutant embryos devoid of microglia confirmed the significant increase of this ratio displayed in protein
 486 extracts from Tg(HuC-hTau^{P301L}:DsRed) embryos microglia-depleted with morpholino. ***, $p <$
 487 0.001 ; **, $p < 0.01$; *, $p < 0.05$. Scale bar (B, C, H, I) = 50 μ m.


488



489 **Figure 3. Microglia phagocytic activity is increased in presence of hTau^{P301L}-expressing, but**
 490 **appears non-sufficient in eliminating all apoptotic neurons.** (A) Schematic illustration of 7 dpf
 491 embryo in dorsal view. The red square shows the region of the optic tectum where the time-lapse (B,
 492 C) was recorded. (B, C) Time-lapse imaging of a microglial cell phagocytosing a diseased neuron (yellow

493 arrowhead) in a 7 dpf Tg(ApoE-eGFP; HuC-hTau^{P301L}:DsRed) embryo; (**B**, Video 3) merge of GFP
494 and DsRed; (**C**) DsRed only. (**D**, $p = 0.0262$) Quantification of the engulfed neuronal volume in
495 Tg(ApoE-eGFP; HuC-RFP) ($n=7$) and Tg(ApoE-eGFP; HuC-hTau^{P301L}:DsRed) ($n=9$) embryos,
496 showing a significantly increased phagocytosis level by microglial cells in the presence of hTau^{P301L}-
497 expressing neurons. (**E-H**, Video 4) Time-lapse image sequences from the optic tectum of a double
498 transgenic Tg(ApoE-eGFP; HuC-hTau^{P301L}:DsRed) 7 dpf embryo, showing a detail of a microglial cell
499 in the process of phagocytosing a neuron labelled with an apoptosis marker, acridine orange (merge: **E**,
500 GFP and acridine: **F**, DsRed only: **G**, acridine only: **H**). The microglial cell filled with other dead
501 tauopathic neurons extends its process to another dying tauopathic neuron and draws it towards its
502 body cell to complete the phagocytosis process. (**I**, $p = 0.027$), Quantification of the number of non-
503 engulfed apoptotic neurons in Tg(ApoE-eGFP; HuC-RFP) ($n=11$) and double transgenic Tg(ApoE-
504 eGFP; HuC-hTau^{P301L}:DsRed) ($n=4$) embryos in which there is a significantly higher number of non-
505 engulfed apoptotic neurons. ***, $p < 0.001$; **, $p < 0.01$; *, $p < 0.05$. Scale bar (B, C, E, F, G, H) = 20
506 μm .

507



508

509 **Figure 4. Summary illustration.** (**A**, **B**) Brain illustrations of control embryo (**A**) and tauopathic
510 embryo (**B**). In the control embryo brain, microglial cells (green) display a highly ramified
511 morphology, allowing them to scan the brain and monitor neighbouring neurons (orange) and eliminate
512 apoptotic ones (blue). However, in presence of hTau^{P301L}-expressing neurons (red), microglial cells
513 (green) adopt an amoeboid morphology, that allows them to move faster throughout the brain in order
514 to eliminate tauopathic neurons undergoing apoptosis (blue). In spite of an increased phagocytic rate
515 of microglial cells in the tauopathic brain, there is a higher number of non-engulfed apoptotic neurons
516 (blue), in comparison to the control brain; thus, suggesting a saturated phagocytic capacity of
517 microglial in the tauopathic brain.